Clinical Trials
982
93 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1850
Active, not recruiting
52
5.3%
Completed
571
58.1%
Enrolling By Invitation
19
1.9%
Not yet recruiting
22
2.2%
Recruiting
131
13.3%
Suspended
2
0.2%
Terminated
125
12.7%
Unknown
4
0.4%
Withdrawn
56
5.7%
No approval data available
- The NIH has awarded a first installment of $4.6 million, part of up to $12.8 million over three years, to a multi-university team modeling drug-hormone interactions in women. - Thirteen researchers from Michigan State, Rutgers, Emory, Tulane, and other institutions will build computational models integrating age and reproductive cycle stage into drug predictions. - The project targets metabolic drugs such as metformin, insulin, and GLP-1 agents, whose effects may vary with shifting female hormone levels. - All computer models and data will be freely available worldwide, with findings intended to inform NIH guidelines and national safety standards.
- XPRIZE announced 20 Finalist Teams advancing in the $101 million Healthspan competition, with 10 teams each receiving $1 million Milestone 2 awards to accelerate clinical development. - The competition aims to restore muscle, cognition, and immune function by a minimum of 10 years in adults aged 50–90, with treatments lasting one year or less. - UC San Diego's Stein Institute will serve as the Central Laboratory and Biorepository, providing standardized multi-omics analysis and biomarker profiling for all finalist teams. - Coordinated clinical trials will run from 2026 to 2029, with the grand prize of up to $81 million to be awarded in 2030.
- Mindfulness-Oriented Recovery Enhancement (MORE) generates a 12-to-1 benefit-to-cost ratio, yielding lifetime savings of $324,489 per patient. - MORE reduced opioid misuse by 45% in the underlying randomized clinical trial of 250 adults with chronic pain misusing prescribed opioids. - The cost-effectiveness of MORE is two to six times greater than residential or intensive outpatient addiction treatment approaches. - Researchers call for wider integration of MORE into health systems, including primary care, to intervene before misuse progresses to severe addiction.
- Lunai Bioworks announced the formation of the Pathfinder Consortium, a national academic-industry alliance designed to accelerate chemical countermeasure development to approximately three years. - The consortium targets $400 million to $1.2 billion U.S. government countermeasure programs by integrating historically fragmented chemical defense capabilities into a unified framework. - The accelerated regulatory pathway includes efficacy demonstration in yeast and cell-based systems, validation in FDA-recognized zebrafish models, two confirmatory animal studies, and a 50-person Phase I safety study. - The initiative leverages BioSymetrics' proprietary AI-enabled phenotypic platform and collaboration with nationally recognized experts from Harvard Medical School, U.S. Air Force Reserve, University of Utah, and Purdue University.
- Recordati Rare Diseases presented four studies at ASH 2025 showcasing advances in Castleman disease understanding, including the first AI-based histopathology grading model for automated diagnosis. - The BURDEN-iMCD study revealed that patients with idiopathic multicentric Castleman disease have 6.9-fold higher morbidity rates and 7.61-fold higher healthcare costs compared to matched controls. - Pediatric analysis from the ACCELERATE registry showed children with iMCD experience more severe disease than adults but respond similarly to siltuximab treatment. - A 20-year cohort study of 217 patients provided new insights into Castleman disease subtypes, confirming TAFRO as the most aggressive form with the poorest survival outcomes.
- Orbus Therapeutics will present updated Phase 3 STELLAR trial results showing eflornithine improves overall survival and progression-free survival in patients with recurrent WHO 2021 grade 3 IDH-mutant astrocytoma. - Eflornithine is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in polyamine biosynthesis that is upregulated in certain cancers. - The drug has received FDA Orphan Drug Designation and Breakthrough Therapy Designation for anaplastic glioma treatment, along with European Medicines Agency Orphan Medicinal Product status. - Results will be presented at the Society for Neuro-Oncology Annual Meeting by Dr. Howard Colman from the Huntsman Cancer Institute at the University of Utah.
- Recordati Rare Diseases will present nine poster presentations at the 67th American Society of Hematology Annual Meeting, showcasing advances in Castleman disease, cold agglutinin disease, and CAR T-cell therapy complications. - Key highlights include the first real-world evaluation of sutimlimab for cold agglutinin disease and an innovative AI model for Castleman disease tissue analysis to improve diagnosis. - The research portfolio demonstrates Recordati's commitment to addressing rare hematologic disorders, with studies covering both pediatric and adult populations across multiple therapeutic areas.
- Researchers at the University of Utah have identified PapB, a naturally-occurring enzyme that can transform linear peptides into stable circular molecules, potentially improving GLP-1 drugs like semaglutide for diabetes and obesity treatment. - The enzyme creates thioether-linked macrocycles without requiring leader sequences, offering a simpler alternative to traditional chemical methods for peptide cyclization and enabling better stability and longer half-life. - PapB's flexibility allows it to work with nonstandard amino acids found in modern incretin drugs, potentially creating next-generation peptide therapeutics that can target previously "undruggable" targets. - The platform could enable multi-target peptide drugs similar to bispecific antibodies but with much smaller molecular size, opening new possibilities for cancer treatment and other disease states.
- A University of Utah study found that COVID-19 infection increases the risk of new-onset depression or anxiety by 49% in children aged 8-17 years, with severe illness raising the risk to 59%. - The research analyzed 154,565 school-aged youth with private insurance or Medicaid coverage, revealing that children with moderate COVID-19 symptoms had a 40% higher likelihood of developing mental health disorders. - Researchers emphasize the need for targeted mental health interventions for infected children as society navigates the post-pandemic landscape. - The study highlights a critical gap in mental health care during the pandemic, when healthcare efforts primarily focused on treating physical symptoms rather than psychological impacts.
- Clinical trials demonstrate that GLP-1 agonist drugs like semaglutide (Ozempic) can lead to a 13.9% loss of lean muscle mass, equivalent to approximately 20 years of age-related muscle decline. - A new preclinical study from University of Utah found that while Ozempic-induced weight loss decreased lean mass by 10% in mice, most loss came from organs like the liver rather than skeletal muscle. - Research indicates muscle strength can decline even when muscle size remains unchanged, raising concerns particularly for adults over 60 who face higher baseline risks for muscle loss. - Prevention strategies include regular resistance training, adequate protein intake, and aerobic exercise, though researchers emphasize the need for more human clinical studies to validate findings.
